First Trust Advisors LP boosted its stake in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 14.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 78,328 shares of the medical research company’s stock after purchasing an additional 9,630 shares during the quarter. First Trust Advisors LP’s holdings in EXACT Sciences were worth $4,115,000 at the end of the most recent reporting period.
A number of other large investors also recently added to or reduced their stakes in EXAS. Dimensional Fund Advisors LP acquired a new position in EXACT Sciences during the 2nd quarter valued at approximately $3,939,000. Raymond James Financial Services Advisors Inc. boosted its position in EXACT Sciences by 97.4% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 38,535 shares of the medical research company’s stock valued at $1,816,000 after purchasing an additional 19,014 shares during the period. Dupont Capital Management Corp acquired a new position in EXACT Sciences during the 3rd quarter valued at approximately $901,000. Chicago Equity Partners LLC acquired a new position in EXACT Sciences during the 3rd quarter valued at approximately $2,312,000. Finally, State of Wisconsin Investment Board boosted its position in EXACT Sciences by 26.2% during the 3rd quarter. State of Wisconsin Investment Board now owns 107,253 shares of the medical research company’s stock valued at $5,054,000 after purchasing an additional 22,253 shares during the period. Institutional investors and hedge funds own 81.10% of the company’s stock.
Shares of EXACT Sciences Co. (EXAS) opened at $52.15 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.77 and a current ratio of 7.15. EXACT Sciences Co. has a twelve month low of $19.91 and a twelve month high of $63.60.
EXAS has been the subject of a number of analyst reports. Robert W. Baird lowered EXACT Sciences from an “outperform” rating to a “neutral” rating and set a $56.00 price objective for the company. in a research report on Monday, November 13th. Leerink Swann reiterated an “outperform” rating and set a $67.00 price target (up previously from $63.00) on shares of EXACT Sciences in a research report on Monday, November 13th. Bank of America boosted their price target on EXACT Sciences from $58.00 to $67.00 and gave the stock a “buy” rating in a research report on Wednesday, November 29th. BidaskClub lowered EXACT Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 6th. Finally, William Blair reiterated a “buy” rating on shares of EXACT Sciences in a research report on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company’s stock. EXACT Sciences currently has a consensus rating of “Buy” and an average price target of $52.84.
In other news, SVP D Scott Coward sold 1,665 shares of the company’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $52.54, for a total value of $87,479.10. Following the completion of the sale, the senior vice president now owns 37,558 shares in the company, valued at $1,973,297.32. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Jeffrey Thomas Elliott sold 2,982 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $42.34, for a total value of $126,257.88. The disclosure for this sale can be found here. In the last 90 days, insiders sold 547,463 shares of company stock valued at $27,045,199. Insiders own 4.00% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “First Trust Advisors LP Has $4.12 Million Position in EXACT Sciences Co. (EXAS)” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3255100/first-trust-advisors-lp-has-4-12-million-position-in-exact-sciences-co-exas.html.
EXACT Sciences Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.